Thoracic US Score Predicts Pleurodesis Success in Malignant Pleural Effusion

Share this content:
In this study, researchers recruited patients who were scheduled to undergo chest tube drainage and talc slurry pleurodesis for the treatment of symptomatic MPE.
In this study, researchers recruited patients who were scheduled to undergo chest tube drainage and talc slurry pleurodesis for the treatment of symptomatic MPE.

Researchers from the University of Oxford in the United Kingdom found that a pleural adherence score derived from thoracic ultrasound (TUS) at 24 hours post-talc administration is predictive of long-term pleurodesis success in patients with symptomatic malignant pleural effusion (MPE). Findings were published in CHEST.

In this prospective observational cohort pilot study (ClinicalTrials.gov Identifier: NCT02625675), the researchers recruited patients who were scheduled to undergo chest tube drainage and talc slurry pleurodesis for the treatment of symptomatic MPE (18 individuals). Immediately before and 24 hours after talc slurry administration, participants underwent a TUS to identify pleural adherence scores for the affected hemithorax. The TUS scans were recorded by 2 independent blinded assessors. Rate of pleurodesis success at 1- and 3-month follow-up comprised the primary outcome.

At 24 hours following talc instillation, a lower pleural adherence score was observed in participants who suffered pleurodesis failure compared with participants who experienced pleurodesis success (difference, 6.27; 95% CI, 3.94-8.59). None of the 11 participants who experienced pleurodesis success at 1-month follow-up experienced delayed failure prior to death (4/11; 36.4%) or at 3-month follow-up (7/11; 63.6%).

The mean TUS-associated pain score on the visual analogue scale was 8.9 mm (SD, 12.9; 95% CI, 1.8-16.1). The TUS scoring was consistent with both assessors (intraclass correlation coefficient, 0.762; 95% CI, 0.605-0.872; P <.001), and patients reported a high level of acceptability of TUS examination.

Limitations of the analysis included the small number of patients as well as recruitment from a center with TUS and pleural disease expertise.

The findings from this study have “implications for individualized TUS-guided management of patients with MPE, but remains an experimental technique.”

Reference

  1. Corcoran JP, Hallifax RJ, Mercer RM, et al. Thoracic ultrasound as an early predictor of pleurodesis success in malignant pleural effusion [published online September 19, 2018]. CHEST. doi:10.1016/j.chest.2018.08.1031

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs